Enar I Carlsson

This inventor holds 9 USPTO granted patents. Top assignees: Aktiebolaget Hassle, E.i. Dupont De Nemours and Company. Active years: 1979-1991.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Enar I Carlsson. Retrieved from https://idiyas.com/inventor/enar-i-carlsson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9

% Patents Active = 100.0

Average Co-Inventor Count = 3.6

ph-index = 4

Forward Citations = 47(Granted Patents)

Location History:

Kungsbacka, SE (1979 - 1982)
Vastra Frolunda, SE (1979 - 1991)

Company Filing History:

E.i. Dupont De Nemours and Company

patents

Years Active: 1979-1991

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5051446 - Substituted 3-phenoxy-1-alkoxycarbonylalkylamino-propanol-2-s having (1991-09-24),

2. 4746667 - Pharmaceutical composition containing 2-(2-benzimidazolyl thiomethyl) (1988-05-24),

3. 4336267 - Heart active compounds and methods of use (1982-06-22),

4. 4263325 - .beta.-Receptor blocking compounds and treatment of cardiovascular (1981-04-21),

5. 4263323 - .beta.-Receptor blocking compounds and treatment of cardiovascular (1981-04-21),

6. 4244969 - Heart active compounds (1981-01-13),

7. 4165384 - Amide substituted phenoxy propanol amines (1979-08-21),

8. 4161542 - Heart active compounds (1979-07-17),

9. 4145442 - Phenoxy-hydroxypropylamines, their preparation, and method and (1979-03-20),

Title: Innovations by Enar I Carlsson: A Pioneering Inventor in Pharmaceuticals

Introduction

Enar I Carlsson, located in Vastra Frolunda, Sweden, is a distinguished inventor with a remarkable portfolio of nine patents. His work primarily revolves around pharmaceutical innovations that address critical health issues, particularly in the field of cardiology.

Latest Patents

One of Carlsson's latest patents is focused on a compound known as substituted 3-phenoxy-1-alkoxycarbonylalkylamino-propanol-2, which relates to the treatment of acute myocardial infarction. This innovative compound possesses beta-adrenoceptor blocking activity and is characterized by its rapid-acting properties, making it suitable for injection administration during acute medical emergencies. Another significant patent involves a pharmaceutical preparation containing the active component 2-(2-benzimidazolyl thiomethyl), along with various therapeutic salts, further demonstrating his contributions to advanced pharmaceutical solutions.

Career Highlights

Throughout his career, Enar I Carlsson worked with prominent companies such as Aktiebolaget Hassle and E.I. DuPont De Nemours and Company. His tenure at these organizations enabled him to contribute significantly to the development of new medical compounds and formulations that hold promise for treating life-threatening conditions.

Collaborations

Carlsson's innovations are often attributed to his collaborative approach, having worked alongside esteemed colleagues like Gustav B Samuelsson and Bo T Lundgren. Their combined expertise has propelled advancements in the pharmaceuticals sector, showcasing the importance of teamwork in pioneering discoveries.

Conclusion

In summary, Enar I Carlsson stands out as a significant figure in the realm of pharmaceutical invention. Through his nine patents, particularly those aimed at treating acute myocardial infarction, Carlsson exemplifies the vital role of innovation in enhancing medical care. His collaborative efforts and impressive career underscore the importance of continuous research and development in improving health outcomes.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]